Understanding treatment patterns in adults with X-linked hypophosphatemia
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows adults already taking burosumab (a medication for X-linked hypophosphatemia, a rare bone disease) to understand how well the treatment works, how it affects blood chemistry, and what outcomes patients experience. The goal is to learn more about real-world treatment of this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–64 years old
- You have been diagnosed with X-linked hypophosphatemia (XLH), confirmed by genetic testing or clinical evaluation
- You have been taking burosumab for at least 90 days and are still using it
- You can attend clinic visits for routine care and study assessments
- You are not currently enrolled in an interventional (treatment-testing) trial
- You have no other serious medical conditions that would make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how young people with X-linked hypophosphataemia (XLH) respond to different doses of burosumab. The goal is to find the best dose to manage the condition.
This early study looks at how the body’s handling of phosphate may affect aging and bone health. It is meant for people with certain rare genetic conditions that change phosphate levels, to better understand their biology and responses to study tests.
This trial tests a single patient's response to an experimental genetic treatment (called an ASO) for a rare brain disease caused by changes in the TUBB4A gene. The goal is to see if the treatment can improve symptoms related to the condition H-ABC.
This study tests a new investigational drug called KK8123 for adults with X-linked hypophosphatemia (XLH). It aims to see if KK8123 can safely raise low blood phosphorus levels. The trial includes two parts and may offer a new treatment option if you have not used burosumab recently.
This registry collects information about people diagnosed with X-linked hypophosphatemia (XLH). It helps researchers better understand the condition and may support future studies by tracking patients over time.
This study follows people who already have hypophosphatasia (HPP) to better understand how the condition changes over time. It may help doctors recognize patterns and improve care, even if you are not receiving a new treatment.
Hear when a new X-linked Hypophosphatemia (XLH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.